ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1465

The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0

Sebastian Rodriguez-Garcia1, Carlos Sanchez-Piedra2, Raul Castellanos-Moreira3, Dolores Ruiz-Montesinos4, Victoria Hernandez5, Manuel Pombo-Suarez6, Fernando Sanchez-Alonso2, Loreto Carmona7 and JJ Gómez-Reino8, 1La Princesa University Hospital, Madrid, Spain, 2Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, 3Hospital Clinic of Barcelona, Barcelona, Spain, 4Hospital Virgen Macarena, Sevilla, Spain, 5Hospital Clínic Barcelona, Barcelona, Spain, 6Hospital Clínico de Santiago, Santiago de Compostela, Spain, 7Instituto de Salud Musculoesquelética, Madrid, Spain, 8IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain

Meeting: ACR Convergence 2020

Keywords: Biologicals, Epidemiology, Infection, registry, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Epidemiology & Public Health I: RA (1462–1466)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens involved. For these patients, the CDC recommends a combined vaccination scheme (CVS) using two types of vaccines but evidence on its effectiveness in this specific population remains insufficient.

Objectives: To assess the impact of the combined vaccination scheme on the incidence of SP infections in patients with RA treated with bDMARD and tsDMARD.

Methods: A cohort was nested in a register including patients with RA who were prescribed a bDMARD or tsDMARD (either naïve or switch) from October 1999 to November 2018. The stem register, BIOBADASER 3.0, is a national multicenter prospective register established in 1999 which recruits patients from 28 tertiary Spanish centers with an estimated national coverage of bDMARD and tsDMARD treatment in RA of 25%. 

Vaccination Status assessment
Each center informed about the date when they implemented a systematic SP vaccination protocol and whether they were using the CVS. Those not adopting the latter were excluded from the analysis.

Outcomes
Invasive pneumococcal disease (IPD) and all-cause community-acquired pneumonia (CAP) were the main outcomes. However, since it is estimated that in a significant proportion of lower respiratory tract infections, SP presence is underdiagnosed, we also included all events reported using relevant MedDRA® codes related to this type of infection. Demographic and clinical features were also retrieved.

Statistical Analysis
Crude incidence rates (IR) were calculated for each outcome and its combination (“All SP-related infections”). Exposure was split into two periods, pre and post-vaccination, considering the date when the CVS was officially recommended in Spain (May 2015).

Poisson regression modelling was carried out to estimate the incidence rate ratio (IRR) comparing both periods. Models were adjusted for potential confounders available such as sex, age, smoking and burden of comorbidity assessed with the Charlson Index which includes conditions such as diabetes mellitus, chronic respiratory diseases, chronic kidney disease, etc.

Results: Study population baseline features
A total of 1704 patients were included, their main features are shown in table 1. All participating centers reported using the CVS except for one that was, therefore, excluded from the analysis. 

Incidence Rates
One-hundred and sixty-seven events were found; 2 for IPD, 136 for CAP and 29 for other lower respiratory tract infections. No IPD events were found in the pre-vac period. The IRs were higher in the pre-vac period for the remaining outcomes. Results are shown in Table 2

Crude and adjusted Incidence Rate Ratios
The IRR for all SP-related infections in the post- vac period was 0.25 (95% CI: 0.13 – 0.47) in the multivariable analysis. (table 3).

Conclusion: The incidence of infections due to SP experienced a decrease in RA patients taking bDMARD or tsDMARD after the introduction of the stepwise combined vaccination scheme that was independent of age, sex, smoking or comorbidities.


Disclosure: S. Rodriguez-Garcia, None; C. Sanchez-Piedra, None; R. Castellanos-Moreira, None; D. Ruiz-Montesinos, None; V. Hernandez, None; M. Pombo-Suarez, None; F. Sanchez-Alonso, None; L. Carmona, Abbvie Spain, 9; J. Gómez-Reino, None.

To cite this abstract in AMA style:

Rodriguez-Garcia S, Sanchez-Piedra C, Castellanos-Moreira R, Ruiz-Montesinos D, Hernandez V, Pombo-Suarez M, Sanchez-Alonso F, Carmona L, Gómez-Reino J. The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0 [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-the-combined-vaccination-scheme-against-streptococcus-pneumoniae-on-the-incidence-of-related-infections-in-patients-with-rheumatoid-arthritis-treated-with-biologic-or-targeted-synthetic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-the-combined-vaccination-scheme-against-streptococcus-pneumoniae-on-the-incidence-of-related-infections-in-patients-with-rheumatoid-arthritis-treated-with-biologic-or-targeted-synthetic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology